Answers are grounded in this paper and cite their sources.
Evaluates ine bilizumab effects on generalized myasthenia gravis, indicating potential benefits for affected adults.
The FDA has approved the CD19-directed cytolytic antibody inebilizumab (Uplizna – Amgen) for IV treatment of generalized myasthenia gravis (gMG) in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The neonatal Fc receptor (FcRn) blockers rozanolixizumab (Rystiggo), nipocalimab (Imaavy), and efgartigimod alfa (Vyvgart; Vyvgart Hytrulo) are also approved for such use (see Table 1).
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: